Dermatology Associates of Seattle

Seattle, Washington 98101-1498

0 studies enrolling now · 14 studies all time

What they study most

Acne Inversa, Actinic Keratosis, Atopic Dermatitis, Axillary Hyperhidrosis, Dermatitis, Dermatitis, Atopic, Eczema, Genetic Diseases, Inborn, Hidradenitis Suppurativa, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases

Studies at this site

• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) — Completed
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) — Completed
• Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) — Completed
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa — Completed
• Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis — Completed
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis — Completed
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects — Completed
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) — Completed
• Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) — Completed
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis — Completed